GlycoMimetics, Inc. (GLYC)

NASDAQ: GLYC · Real-Time Price · USD
0.330
-0.049 (-12.95%)
At close: Nov 20, 2024, 4:00 PM
0.311
-0.019 (-5.67%)
Pre-market: Nov 21, 2024, 7:39 AM EST
-12.95%
Market Cap 21.28M
Revenue (ttm) 10,000
Net Income (ttm) -39.74M
Shares Out 64.48M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,459,408
Open 0.350
Previous Close 0.379
Day's Range 0.310 - 0.369
52-Week Range 0.140 - 3.530
Beta 1.84
Analysts Hold
Price Target 12.00 (+3,536.36%)
Earnings Date Nov 13, 2024

About GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protei... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2014
Employees 35
Stock Exchange NASDAQ
Ticker Symbol GLYC
Full Company Profile

Financial Performance

In 2023, GlycoMimetics's revenue was $10,000, a decrease of -86.67% compared to the previous year's $75,000. Losses were -$36.90 million, -20.97% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for GLYC stock is "Hold." The 12-month stock price forecast is $12.0, which is an increase of 3,536.36% from the latest price.

Price Target
$12.0
(3,536.36% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc...

9 days ago - PRNewsWire

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been...

15 days ago - Business Wire

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...

20 days ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

Other symbols: PFIE
22 days ago - PRNewsWire

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnol...

23 days ago - Business Wire

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

23 days ago - Business Wire

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

4 months ago - Business Wire

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

6 months ago - Business Wire

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...

6 months ago - Business Wire

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics, Inc. (NASDAQ:GLYC) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer ...

6 months ago - Seeking Alpha

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

7 months ago - Business Wire

GlycoMimetics: Is No News Bad News?

GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan, has shown promising results in early-stage clinical trials ...

7 months ago - Seeking Alpha

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, ...

7 months ago - Business Wire

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

8 months ago - Seeking Alpha

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

8 months ago - Business Wire

GlycoMimetics Can Become A Game Changer In Blood Cancers

GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor p...

8 months ago - Seeking Alpha

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We...

9 months ago - Business Wire

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Heal...

9 months ago - Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 6,...

10 months ago - Business Wire

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer. The company's most advanced project, Uproleselan, has recently shown promising results in a p...

10 months ago - Seeking Alpha

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

11 months ago - Business Wire

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthca...

1 year ago - Business Wire

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer...

1 year ago - Seeking Alpha

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...

1 year ago - Business Wire